OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Italian adaptation of EuroGuiDerm guideline on the systemic treatment of chronic plaque psoriasis
Paolo Gisondi, Maria Concetta Fargnoli, Paolo Amerio, et al.
Italian Journal of Dermatology and Venereology (2022) Vol. 157
Open Access | Times Cited: 63
Paolo Gisondi, Maria Concetta Fargnoli, Paolo Amerio, et al.
Italian Journal of Dermatology and Venereology (2022) Vol. 157
Open Access | Times Cited: 63
Showing 1-25 of 63 citing articles:
Effectiveness and safety of bimekizumab for the treatment of plaque psoriasis: a real-life multicenter study—IL PSO (Italian landscape psoriasis)
Luigi Gargiulo, Alessandra Narcisi, Luciano Ibba, et al.
Frontiers in Medicine (2023) Vol. 10
Open Access | Times Cited: 43
Luigi Gargiulo, Alessandra Narcisi, Luciano Ibba, et al.
Frontiers in Medicine (2023) Vol. 10
Open Access | Times Cited: 43
Drug survival of IL-12/23, IL-17 and IL-23 inhibitors for moderate-to-severe plaque psoriasis: a retrospective multicenter real-world experience on 5932 treatment courses – IL PSO (Italian landscape psoriasis)
Luigi Gargiulo, Luciano Ibba, Piergiorgio Malagoli, et al.
Frontiers in Immunology (2024) Vol. 14
Open Access | Times Cited: 22
Luigi Gargiulo, Luciano Ibba, Piergiorgio Malagoli, et al.
Frontiers in Immunology (2024) Vol. 14
Open Access | Times Cited: 22
Bimekizumab for the Treatment of Plaque Psoriasis With Involvement of Genitalia: A 16-Week Multicenter Real-World Experience—IL PSO (Italian Landscape Psoriasis)
Diego Orsini, Piergiorgio Malagoli, Anna Balato, et al.
Dermatology Practical & Conceptual (2024) Vol. 14, Iss. 2, pp. e2024052-e2024052
Open Access | Times Cited: 17
Diego Orsini, Piergiorgio Malagoli, Anna Balato, et al.
Dermatology Practical & Conceptual (2024) Vol. 14, Iss. 2, pp. e2024052-e2024052
Open Access | Times Cited: 17
Real‐life effectiveness and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: A 104‐week multicenter retrospective study – IL PSO (ITALIAN LANDSCAPE PSORIASIS )
Luigi Gargiulo, Luciano Ibba, Piergiorgio Malagoli, et al.
Journal of the European Academy of Dermatology and Venereology (2023) Vol. 37, Iss. 5, pp. 1017-1027
Open Access | Times Cited: 25
Luigi Gargiulo, Luciano Ibba, Piergiorgio Malagoli, et al.
Journal of the European Academy of Dermatology and Venereology (2023) Vol. 37, Iss. 5, pp. 1017-1027
Open Access | Times Cited: 25
Brodalumab for the treatment of plaque psoriasis in a real-life setting: a 3 years multicenter retrospective study—IL PSO (Italian landscape psoriasis)
Luigi Gargiulo, Luciano Ibba, Piergiorgio Malagoli, et al.
Frontiers in Medicine (2023) Vol. 10
Open Access | Times Cited: 23
Luigi Gargiulo, Luciano Ibba, Piergiorgio Malagoli, et al.
Frontiers in Medicine (2023) Vol. 10
Open Access | Times Cited: 23
Comparing clinical trial population representativeness to real-world users of 17 biologics approved for immune-mediated inflammatory diseases: An external validity analysis of 66,639 biologic users from the Italian VALORE project
Ylenia Ingrasciotta, Andrea Spini, Luca L’Abbate, et al.
Pharmacological Research (2024) Vol. 200, pp. 107074-107074
Open Access | Times Cited: 16
Ylenia Ingrasciotta, Andrea Spini, Luca L’Abbate, et al.
Pharmacological Research (2024) Vol. 200, pp. 107074-107074
Open Access | Times Cited: 16
Safety of interleukin inhibitors in patients with plaque psoriasis and history of neoplasms: a multicenter retrospective study – IL PSO (Italian landscape psoriasis)
Mario Valenti, Luciano Ibba, S. Di Giulio, et al.
Journal of Dermatological Treatment (2025) Vol. 36, Iss. 1
Open Access | Times Cited: 1
Mario Valenti, Luciano Ibba, S. Di Giulio, et al.
Journal of Dermatological Treatment (2025) Vol. 36, Iss. 1
Open Access | Times Cited: 1
Real-Life Effectiveness and Safety of Risankizumab in 131 Patients Affected by Moderate-to-Severe Plaque Psoriasis: A 52-Week Retrospective Study
Luigi Gargiulo, Luciano Ibba, Giulia Pavia, et al.
Dermatology and Therapy (2022) Vol. 12, Iss. 10, pp. 2309-2324
Open Access | Times Cited: 32
Luigi Gargiulo, Luciano Ibba, Giulia Pavia, et al.
Dermatology and Therapy (2022) Vol. 12, Iss. 10, pp. 2309-2324
Open Access | Times Cited: 32
Real‐life effectiveness of tildrakizumab in chronic plaque psoriasis: A 52‐week multicentre retrospective study—IL PSO (Italian landscape psoriasis )
Alessandra Narcisi, Mario Valenti, Luigi Gargiulo, et al.
Journal of the European Academy of Dermatology and Venereology (2022) Vol. 37, Iss. 1, pp. 93-103
Open Access | Times Cited: 32
Alessandra Narcisi, Mario Valenti, Luigi Gargiulo, et al.
Journal of the European Academy of Dermatology and Venereology (2022) Vol. 37, Iss. 1, pp. 93-103
Open Access | Times Cited: 32
Effectiveness, Tolerability, and Drug Survival of Risankizumab in a Real-World Setting: A Three-Year Retrospective Multicenter Study—IL PSO (ITALIAN LANDSCAPE PSORIASIS)
Luigi Gargiulo, Luciano Ibba, Piergiorgio Malagoli, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 2, pp. 495-495
Open Access | Times Cited: 8
Luigi Gargiulo, Luciano Ibba, Piergiorgio Malagoli, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 2, pp. 495-495
Open Access | Times Cited: 8
Efficacy and safety of tildrakizumab in elderly patients: real-world multicenter study (ESTER – study)
Diego Orsini, Giacomo Caldarola, Annunziata Dattola, et al.
Journal of Dermatological Treatment (2024) Vol. 35, Iss. 1
Open Access | Times Cited: 7
Diego Orsini, Giacomo Caldarola, Annunziata Dattola, et al.
Journal of Dermatological Treatment (2024) Vol. 35, Iss. 1
Open Access | Times Cited: 7
Psoriasis and Molecular Target Therapies: Evidence of Efficacy in Preventing Cardiovascular Comorbidities
Luca Potestio, Nello Tommasino, Giuseppe Lauletta, et al.
Dermatology and Therapy (2024) Vol. 14, Iss. 4, pp. 841-852
Open Access | Times Cited: 6
Luca Potestio, Nello Tommasino, Giuseppe Lauletta, et al.
Dermatology and Therapy (2024) Vol. 14, Iss. 4, pp. 841-852
Open Access | Times Cited: 6
JAK Inhibitors in Psoriatic Disease
Matteo Megna, Luca Potestio, Angelo Ruggiero, et al.
Clinical Cosmetic and Investigational Dermatology (2023) Vol. Volume 16, pp. 3129-3145
Open Access | Times Cited: 16
Matteo Megna, Luca Potestio, Angelo Ruggiero, et al.
Clinical Cosmetic and Investigational Dermatology (2023) Vol. Volume 16, pp. 3129-3145
Open Access | Times Cited: 16
A Multidisciplinary Approach Is Beneficial in Atopic Dermatitis
Paolo Amerio, Silvia Ferrucci, Marco Galluzzo, et al.
Dermatology and Therapy (2024) Vol. 14, Iss. 6, pp. 1443-1455
Open Access | Times Cited: 6
Paolo Amerio, Silvia Ferrucci, Marco Galluzzo, et al.
Dermatology and Therapy (2024) Vol. 14, Iss. 6, pp. 1443-1455
Open Access | Times Cited: 6
Comparative effectiveness of tildrakizumab 200 mg versus tildrakizumab 100 mg in psoriatic patients with high disease burden or above 90 kg of body weight: a 16-week multicenter retrospective study – IL PSO (Italian landscape psoriasis)
Luigi Gargiulo, Luciano Ibba, Ruggero Cascio Ingurgio, et al.
Journal of Dermatological Treatment (2024) Vol. 35, Iss. 1
Open Access | Times Cited: 5
Luigi Gargiulo, Luciano Ibba, Ruggero Cascio Ingurgio, et al.
Journal of Dermatological Treatment (2024) Vol. 35, Iss. 1
Open Access | Times Cited: 5
Psoriasis in women with psoriatic arthritis: hormonal effects, fertility, and considerations for management at different stages of life
Fortunato Cassalia, Anna Belloni Fortina
Reumatismo (2024) Vol. 76, Iss. 3
Open Access | Times Cited: 5
Fortunato Cassalia, Anna Belloni Fortina
Reumatismo (2024) Vol. 76, Iss. 3
Open Access | Times Cited: 5
New-onset and flares of psoriasis after COVID-19 infection or vaccination successfully treated with biologics: a case series
Luigi Gargiulo, Luciano Ibba, Carlo Alberto Vignoli, et al.
Journal of Dermatological Treatment (2023) Vol. 34, Iss. 1
Open Access | Times Cited: 12
Luigi Gargiulo, Luciano Ibba, Carlo Alberto Vignoli, et al.
Journal of Dermatological Treatment (2023) Vol. 34, Iss. 1
Open Access | Times Cited: 12
Brodalumab for the Treatment of Moderate-to-Severe Psoriasis: An Expert Delphi Consensus Statement
Maria Concetta Fargnoli, Federico Bardazzi, Luca Bianchi, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 10, pp. 3545-3545
Open Access | Times Cited: 11
Maria Concetta Fargnoli, Federico Bardazzi, Luca Bianchi, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 10, pp. 3545-3545
Open Access | Times Cited: 11
Long-Term Effectiveness and Safety of Ixekizumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: A Five-Year Multicenter Retrospective Study—IL PSO (Italian Landscape Psoriasis)
Mario Valenti, Luigi Gargiulo, Luciano Ibba, et al.
Dermatology and Therapy (2024) Vol. 14, Iss. 6, pp. 1649-1657
Open Access | Times Cited: 4
Mario Valenti, Luigi Gargiulo, Luciano Ibba, et al.
Dermatology and Therapy (2024) Vol. 14, Iss. 6, pp. 1649-1657
Open Access | Times Cited: 4
Validation and application of the Dermatology Life Quality Index score, a modification of the DLQI score, in psoriasis patients
Qin Zou, Yi‐Bo Luo, Dan Hao, et al.
Journal of Health Population and Nutrition (2024) Vol. 43, Iss. 1
Open Access | Times Cited: 4
Qin Zou, Yi‐Bo Luo, Dan Hao, et al.
Journal of Health Population and Nutrition (2024) Vol. 43, Iss. 1
Open Access | Times Cited: 4
A risankizumab super responder profile identified by long‐term real‐life observation‐IL PSO (ITALIAN LANDSCAPE PSORIASIS )
Luigi Gargiulo, Luciano Ibba, Piergiorgio Malagoli, et al.
Journal of the European Academy of Dermatology and Venereology (2023) Vol. 38, Iss. 1
Open Access | Times Cited: 10
Luigi Gargiulo, Luciano Ibba, Piergiorgio Malagoli, et al.
Journal of the European Academy of Dermatology and Venereology (2023) Vol. 38, Iss. 1
Open Access | Times Cited: 10
Baricitinib Provides Significant Improvements in Quality of Life and Functioning in Adults with Moderate-to-Severe Atopic Dermatitis with Baseline Body Surface Area ≤ 40% and Severe Itch
Matthias Augustin, Maddalena Napolitano, Rosa Izu-Belloso, et al.
Dermatology and Therapy (2025)
Open Access
Matthias Augustin, Maddalena Napolitano, Rosa Izu-Belloso, et al.
Dermatology and Therapy (2025)
Open Access
Effectiveness, speed of action and safety of brodalumab in elderly psoriasis patients: a multicenter real-world study – IL PSO (Italian Landscape Psoriasis)
Diego Orsini, Dario Graceffa, Martina Burlando, et al.
Journal of Dermatological Treatment (2025) Vol. 36, Iss. 1
Open Access
Diego Orsini, Dario Graceffa, Martina Burlando, et al.
Journal of Dermatological Treatment (2025) Vol. 36, Iss. 1
Open Access
Effectiveness of Brodalumab for the Treatment of Moderate-to-Severe Psoriasis: A Retrospective, Real-World Multicenter Study with a Focus on Obese and Multi-Failure Patients—IL PSO (Italian Landscape Psoriasis)
Diego Orsini, Dario Graceffa, Martina Burlando, et al.
Journal of Clinical Medicine (2025) Vol. 14, Iss. 4, pp. 1087-1087
Open Access
Diego Orsini, Dario Graceffa, Martina Burlando, et al.
Journal of Clinical Medicine (2025) Vol. 14, Iss. 4, pp. 1087-1087
Open Access
Bimekizumab for the treatment of moderate to severe psoriasis: a real-world experience over 52 weeks from two Italian dermatology clinics
Edoardo Mortato, Fabio Artosi, Cristiana Borselli, et al.
Journal of Dermatological Treatment (2025) Vol. 36, Iss. 1
Open Access
Edoardo Mortato, Fabio Artosi, Cristiana Borselli, et al.
Journal of Dermatological Treatment (2025) Vol. 36, Iss. 1
Open Access
